MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate is AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The company is also developing MedTone and Dreamboat inhaler devices. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool

• [01/02/2015 05:12 PST] MNKD Expected to Trade Down Short Term
• [12/25/2014 21:41 PST] MNKD Are Seasonally Ripe To Go Down In the Next Five Weeks
• [12/12/2014 04:51 PST] MNKD Expected to Trade Down Short Term
• [12/05/2014 05:10 PST] MNKD, Expected to Trade Lower After Bearish Insider Trading
• [12/04/2014 05:00 PST] Mannkind Corp (NASDAQ:MNKD), Down By 5.26% ($0.30) From $5.700 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [12/04/2014 05:00 PST] MNKD, Expected to Trade Lower After Bearish Insider Trading
• [11/28/2014 05:19 PST] Mannkind Corp (NASDAQ:MNKD), Down By 10.54% ($0.66) From $6.260 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [11/28/2014 05:19 PST] MNKD, Expected to Trade Lower After Bearish Insider Trading